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CASE 1
Case 1 is a 79-year-old woman with a significant
smoking history, who underwent a nephrectomy for renal cell
carcinoma (RCC) 14 years before presentation. A chest
computed tomography (CT) scan demonstrated a left upper
lobe 14  12 mm spiculated peripheral nodule, and an 8-mm
central lobar nodule (Figure 1). A positron emission tomog-
raphy scan demonstrated activity in the peripheral dominant
lesion. The patient underwent a video-assisted thoracic sur-
gery (VATS) wedge resection of the peripheral lesion. Frozen
section histology demonstrated adenocarcinoma. A complete
VATS lobectomy was performed with mediastinal lymph
node sampling. On final pathology, the peripheral lesion was
metastatic RCC, and the central lesion was a pulmonary
adenocarcinoma confirmed by Thyroid Transcription Factor 1
positivity; all lymph nodes were normal.
CASE 2
Case 2 is a 49-year-old male smoker who 4 months
prior underwent a left nephrectomy for RCC. A follow-up CT
scan demonstrated two right upper lobe nodules: a 14 
24-mm dominant central lesion (Figure 2A) and a 7-mm
subpleural nodule (Figure 2B). A positron emission tomog-
raphy/CT scan showed activity in the central lesion only. A
CT-guided biopsy of the central lesion demonstrated meta-
static RCC. After smoking cessation, the patient underwent a
VATS right upper lobe lobectomy with mediastinal lymph
node sampling. Pathology confirmed that the dominant lesion
was a metastatic RCC (Figure 3A), the subpleural lesion was
a pulmonary adenocarcinoma (Figure 3B), with all lymph-
nodes normal.
DISCUSSION
Pulmonary metastasectomy for metastatic RCC may
afford 5-year survival of more than 30%.1 Evaluation of
potential RCC metastasis in the patient who is also at risk for
primary lung cancer is challenging. The decision to not
perform an anatomic resection for a suspected metastatic
lesion, amenable only to lobectomy, may undertreat an occult
primary lung cancer. A review of the literature revealed two
other reports of synchronous metastatic RCC and primary
non-small cell lung cancer (NSCLC). Shiraishi et al.2 re-
ported one patient with synchronous NSCLC and RCC that
were excised by VATS sublobar resection. Higashiyama et
al.3 described two patients who underwent sublobar resection
of synchronous NSCLC and RCC.
In our Case 2, the biopsy-proven RCC was a central
lesion resectable only by lobectomy and the peripheral lesion
was assumed to be an additional RCC metastasis. Lobectomy
for metastatic RCC is controversial given the high rate of
disease recurrence. One option would have been parenchyma
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FIGURE 1. Contrast-enhanced axial computed tomography
scan demonstrates a left upper lobe peripheral 14  12 mm
spiculated nodule (arrow) and an 8-mm central lobar nodule
(oval).
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preserving radiofrequency ablation of both lesions. However,
radiofrequency ablation therapy in this case would have
undertreated the NSCLC.
Ideally, in patients with metastatic RCC who are high
risk for lung cancer, there would be avenues for preoperative
differentiation of metastatic RCC from primary pulmonary
neoplasms. Routine CT-guided biopsy of all pulmonary le-
sions may distinguish NSCLC from metastases, but is not
always practical. Newer technology, such as navigational
bronchoscopic-guided biopsy, might allow the surgeon to
distinguish primary and secondary lesions preoperatively.4
In conclusion, careful multidisciplinary approaches
should be applied to patients with pulmonary metastatic RCC
who are at high risk for NSCLC. Defaulting to lung-preserv-
ing therapy, without excluding primary NSCLC, may under-
treat a subpopulation of early-stage NSCLC patients.
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FIGURE 2. A, Contrast-enhanced axial
computed tomography scan illustrates a
right upper lobe 14  24 mm dominant
central lesion (oval) and (B) a 7-mm sub-
pleural nodule (arrow).
FIGURE 3. A, High-powered micrograph
of a metastatic clear cell renal carcinoma. B,
High-powered micrograph of a primary
well-differentiated lung adenocarcinoma.
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